INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

作者：Danny Rischin, Aaron R. Hansen, Ezra E.W. Cohen, Makoto Tahara, Kevin J. Harrington, Robert I. Haddad, L. Licitra, H. Mehanna, Robert L. Ferris, P. Koralewski, Konstantin Penkov, Michael Schenker, David R. Spigel, Amaury Daste, Min Hee Hong, Y. Guo, Michael Chisamore, Michael L. Washburn, Amy Phillips-Jones, John Russell, Sumita Roy-Ghanta, C. E. Ellis, Marc Ballas, C. Le Tourneau · 发表于：Clinical Cancer Research · 年份：2025 · DOI：10.1158/1078-0432.ccr-25-1197 · 被引用次数：2 · 研究领域：Cancer Immunotherapy and Biomarkers、CAR-T cell therapy research、Head and Neck Cancer Studies

PURPOSE: Feladilimab, an inducible T-cell costimulatory receptor agonist, demonstrated clinical activity in combination with pembrolizumab in a phase I head and neck squamous cell carcinoma (HNSCC) expansion cohort, prompting further evaluation in patients in this setting. PATIENTS AND METHODS: INDUCE-3 (NCT04128696) was a randomized, double-blind, phase II/III study in patients with first-line PD-L1-positive recurrent and/or metastatic HNSCC. A 2-in-1 adaptive design was implemented, with an option to expand the phase II study into a phase III confirmatory study. Patients were randomized 1:1 to receive feladilimab plus pembrolizumab or placebo plus pembrolizumab, with up to 35 cycles of treatment for approximately 2 years. Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS). RESULTS: The study enrolled 315 patients. Following the review of unblinded interim data in 140 patients, an Independent Data Monitoring Committee recommended stopping patient accrual based on prespecified criteria. Existing patients discontinued feladilimab or placebo. Pembrolizumab treatment continued until prespecified stopping criteria were met. This study demonstrated no evidence of an effect in favor of feladilimab plus pembrolizumab, with an adjusted HR of 1.51 for OS and 1.40 for PFS (median OS: 44.1 weeks [95% confidence interval (CI), 35.9-not applicable]; median PFS: 10.1 weeks [95% CI, 9.1-15]) versus placebo plus pembrolizumab [median OS: no...